A detailed history of Credit Suisse Ag transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 321,946 shares of KRYS stock, worth $53.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
321,946
Previous 474,484 32.15%
Holding current value
$53.1 Million
Previous $58.9 Million 2.69%
% of portfolio
0.06%
Previous 0.06%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$108.01 - $179.35 $16.5 Million - $27.4 Million
-152,538 Reduced 32.15%
321,946 $57.3 Million
Q4 2023

Feb 08, 2024

BUY
$96.0 - $128.29 $23.1 Million - $30.9 Million
240,863 Added 103.1%
474,484 $58.9 Million
Q3 2023

Nov 13, 2023

SELL
$108.51 - $130.22 $25.3 Million - $30.4 Million
-233,567 Reduced 49.99%
233,621 $27.1 Million
Q2 2023

Aug 11, 2023

SELL
$78.48 - $130.32 $13 Million - $21.6 Million
-165,636 Reduced 26.17%
467,188 $54.8 Million
Q1 2023

May 10, 2023

SELL
$72.39 - $84.27 $3.62 Million - $4.22 Million
-50,056 Reduced 7.33%
632,824 $50.7 Million
Q4 2022

Feb 13, 2023

BUY
$63.14 - $79.9 $278,447 - $352,359
4,410 Added 0.65%
682,880 $54.1 Million
Q3 2022

Nov 10, 2022

SELL
$64.85 - $82.4 $1.58 Million - $2.01 Million
-24,433 Reduced 3.48%
678,470 $47.3 Million
Q2 2022

Aug 12, 2022

SELL
$48.93 - $73.47 $2.69 Million - $4.04 Million
-54,956 Reduced 7.25%
702,903 $46.2 Million
Q1 2022

May 16, 2022

BUY
$51.99 - $72.11 $217,266 - $301,347
4,179 Added 0.55%
757,859 $50.4 Million
Q4 2021

Feb 14, 2022

SELL
$39.81 - $88.24 $727,487 - $1.61 Million
-18,274 Reduced 2.37%
753,680 $52.7 Million
Q3 2021

Nov 12, 2021

BUY
$52.01 - $71.77 $292,764 - $403,993
5,629 Added 0.73%
771,954 $40.3 Million
Q2 2021

Aug 16, 2021

SELL
$62.14 - $81.82 $812,480 - $1.07 Million
-13,075 Reduced 1.68%
766,325 $52.1 Million
Q1 2021

May 14, 2021

BUY
$59.42 - $85.46 $230,074 - $330,901
3,872 Added 0.5%
779,400 $60 Million
Q4 2020

Feb 12, 2021

BUY
$40.64 - $61.38 $51,775 - $78,198
1,274 Added 0.16%
775,528 $46.5 Million
Q3 2020

Nov 13, 2020

BUY
$37.76 - $48.49 $3.46 Million - $4.45 Million
91,710 Added 13.44%
774,254 $33.3 Million
Q2 2020

Aug 12, 2020

BUY
$37.03 - $60.0 $3.78 Million - $6.13 Million
102,108 Added 17.59%
682,544 $28.3 Million
Q1 2020

May 13, 2020

BUY
$35.02 - $65.64 $10.5 Million - $19.7 Million
299,818 Added 106.84%
580,436 $25.1 Million
Q4 2019

Feb 12, 2020

BUY
$33.17 - $65.23 $7.06 Million - $13.9 Million
212,981 Added 314.89%
280,618 $15.5 Million
Q3 2019

Nov 12, 2019

SELL
$34.72 - $51.3 $54,684 - $80,797
-1,575 Reduced 2.28%
67,637 $2.35 Million
Q2 2019

Aug 14, 2019

BUY
$27.2 - $41.2 $1.88 Million - $2.85 Million
69,212 New
69,212 $2.79 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.23B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.